News Brilique boosted by NICE’s long-term prevention recommendati... Recommendation will add to growth trajectory
News AZ's key drug Brilique fails in stroke trial Disappointment for AstraZeneca and key growth driver
News JPM: AbbVie pays $650m upfront for RemeGen cancer drug AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
